DC Chemicals Limited
China
Product Name: AS-1413(Amonafide)
Price: $350.0/100mg $700.0/250mg $1400.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

69408-81-7

69408-81-7 structure

69408-81-7 structure

Name: Amonafide
Chemical Name: 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione
CAS Number: 69408-81-7
Molecular Formula: C₁₆H₁₇N₃O₂
Molecular Weight: 283.325
Catalog: Biochemical Inhibitor DNA damage Topoisomerase inhibitor
Create Date: 2018-09-25 13:07:10
Modify Date: 2024-01-03 01:39:33
Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.

Name	5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione
Synonyms	Amonifide 5-amino-2-[(dimethylamine)ethyl]-1H-benz[de-]isoquinoline-1,3-(2H)-dione amonafide 1H-Benz[de]isoquinoline-1,3(2H)-dione, 5-amino-2-[2-(dimethylamino)ethyl]- AS-1413 5-Aminomitonafide Nafidimide Benzisoquinolinedione Quinamed Amonafidum [Latin] 5-Amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione 2-(2-dimethylaminoethyl)-5-aminobenzo[de]isoquinoline-1,3-dione 5-amino-2-(2-(dimethylamino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione Xanafide

Description	Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.
Related Catalog	Research Areas >> Cancer
Target	Topoisomerase II
In Vitro	Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA[1]. Amonafide produces protein-associated DNA cleavage, single-strand breaks (SSB) and DPC and DNA double-strand cleavage. Amonafide (Nafidimide, 400 nM-2.4 μM) reduces the colony-forming ability of the leukemic cell lines in a dose-dependent manner[2]. Amonafide (0.05-0.4 μg/mL) reduces several tumor growth. However, Amonafide is active against only 12% of tumors compared with standard agents (5-fluorouracil, mitomycin C, cisplatin, and etoposide), which are active against more than 40% of tumors in the human bone marrow inhibitory range[3]. Amonafide inhibits the growth of HT-29, HeLa, and PC-3 cell lines, with IC50s of 4.67, 2.73, and 6.38 μM[4].
Cell Assay	In experiments measuring survival following 1 h drug treatments, 2 × 106cells are resuspended in 2 mL warm (37°C) HBSS with 5% PCS; the appropriate drug (Amonafide) level is attained with the addition of less than 50 μL. Cells are incubated for 60 min at 37°C after which 10 mL ice cold PBS is added. The cells are then centrifuged at 200 × g for 10 min at 4°C. The wash is repeated once and the cells are resuspended in HBSS with 5% PCS and added to the agar-medium mixture for assessment of surviving clonogenic cells[2].
References	[1]. Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. [2]. Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. [3]. Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85.

Density	1.3±0.1 g/cm3
Boiling Point	500.2±35.0 °C at 760 mmHg
Melting Point	162-164ºC
Molecular Formula	C₁₆H₁₇N₃O₂
Molecular Weight	283.325
Flash Point	256.3±25.9 °C
Exact Mass	283.132080
PSA	68.33000
LogP	0.06
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.681
Storage condition	-20°C Freezer

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QK5610000

CHEMICAL NAME :: Naphthalimide, 3-amino-N-(2-(dimethylamino)ethyl)-

CAS REGISTRY NUMBER :: 69408-81-7

LAST UPDATED :: 199612

DATA ITEMS CITED :: 5

MOLECULAR FORMULA :: C16-H17-N3-O2

MOLECULAR WEIGHT :: 283.36

WISWESSER LINE NOTATION :: T666 1A M CVNVT&&J D2N1&1 HZ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 67 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >18400 ug/kg

TOXIC EFFECTS :: Behavioral - tremor Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - changes in structure or function of salivary glands

MUTATION DATA

TYPE OF TEST :: DNA damage

TEST SYSTEM :: Rodent - mouse Leukocyte

DOSE/DURATION :: 50 umol/L

REFERENCE :: BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958- Volume(issue)/page/year: 34,3845,1985

54824-17-8 structure

54824-17-8

~99%

69408-81-7 structure

69408-81-7

Literature: Quintana-Espinoza, Patricia; Garcia-Luis, Jonay; Amesty, Angel; Martin-Rodriguez, Patricia; Lorenzo-Castrillejo, Isabel; Ravelo, Angel G.; Fernandez-Perez, Leandro; Machin, Felix; Estevez-Braun, Ana Bioorganic and Medicinal Chemistry, 2013 , vol. 21, # 21 p. 6484 - 6495

3027-38-1 structure

3027-38-1

~%

69408-81-7 structure

69408-81-7

Literature: Journal of Medicinal Chemistry, , vol. 50, # 17 p. 4122 - 4134

23204-38-8 structure

23204-38-8

108-00-9 structure

108-00-9

~83%

69408-81-7 structure

69408-81-7

Literature: Cui, Lei; Zhong, Ye; Zhu, Weiping; Xu, Yufang; Qian, Xuhong Chemical Communications, 2010 , vol. 46, # 38 p. 7121 - 7123

81-84-5 structure

81-84-5

~%

69408-81-7 structure

69408-81-7

Literature: European Journal of Medicinal Chemistry, , vol. 47, # 1 p. 546 - 552

Precursor 5
54824-17-8 3027-38-1 23204-38-8 108-00-9
81-84-5
DownStream 1
69409-02-5